UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC

Lung cancer (Amsterdam, Netherlands), 2019-01, Vol.127, p.153-163

2019

Volltextzugriff (PDF)

Palliative Short-Course Radiation Therapy in Rectal Cancer: A Phase 2 Study

International journal of radiation oncology, biology, physics, 2016-07, Vol.95 (4), p.1184-1190

2016

Volltextzugriff (PDF)

Gene mutations in small-cell lung cancer (SCLC): Results of a panel of 6 genes in a cohort of Italian patients

Lung cancer (Amsterdam, Netherlands), 2014-12, Vol.86 (3), p.324-328

2014

Volltextzugriff (PDF)

Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: A pooled analysis of topotecan second-line trials

European journal of cancer (1990), 2014-09, Vol.50 (13), p.2211-2218

2014

Volltextzugriff (PDF)

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

The lancet oncology, 2019-12, Vol.20 (12), p.1655-1669

2019

Volltextzugriff (PDF)

PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non–small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors

Clinical lung cancer, 2021-09, Vol.22 (5), p.423-431

2021

Volltextzugriff (PDF)

Patterns of renal toxicity from the combination of pemetrexed and pembrolizumab for advanced nonsquamous non-small-cell lung cancer (NSCLC): A single-center experience

Lung cancer (Amsterdam, Netherlands), 2022-12, Vol.174, p.91-96

2022

Volltextzugriff (PDF)

The pathogenic and colonization potential of Candida africana

Microbes and infection, 2024-01, Vol.26 (1-2), p.105230, Article 105230

2024

Volltextzugriff (PDF)

Prognostic role of hyponatremia in 564 small cell lung cancer patients treated with topotecan

Lung cancer (Amsterdam, Netherlands), 2014-10, Vol.86 (1), p.91-95

2014

Volltextzugriff (PDF)

Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME)

Cancer treatment reviews, 2018-12, Vol.71, p.76-87

2018

Volltextzugriff (PDF)

BOLERO-3 results: pharmacological activity or pharmacokinetic effect?

The lancet oncology, 2014-07, Vol.15 (8), p.e304-e304

2014

Volltextzugriff (PDF)

Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC)

Lung cancer (Amsterdam, Netherlands), 2014-02, Vol.83 (2), p.265-271

2014

Volltextzugriff (PDF)

Evaluation of the VeriStrat® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study

Lung cancer (Amsterdam, Netherlands), 2017-07, Vol.109, p.101-108

2017

Volltextzugriff (PDF)

Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) study

Lung cancer (Amsterdam, Netherlands), 2015-11, Vol.90 (2), p.234-242

2015

Volltextzugriff (PDF)

Overcoming Primary Resistance to PD-1 Inhibitor With Anti–PD-L1 Agent in Squamous-Cell NSCLC: Case Report

Clinical lung cancer, 2020-03, Vol.21 (2), p.e45-e48

2020

Volltextzugriff (PDF)

Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed–carboplatin

Lung cancer (Amsterdam, Netherlands), 2012-10, Vol.78 (1), p.92-99

2012

Volltextzugriff (PDF)

Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): Study of a comprehensive panel of molecular markers

Lung cancer (Amsterdam, Netherlands), 2010-03, Vol.67 (3), p.355-360

2010

Volltextzugriff (PDF)

Different clinical effects upon separate inhibition of coexisting EGFR and PI3KCA mutations in a lung adenocarcinoma patient

Lung cancer (Amsterdam, Netherlands), 2015-02, Vol.87 (2), p.204-206

2015

Volltextzugriff (PDF)

Preoperative Chemoradiation with VMAT-SIB in Rectal Cancer: A Phase II Study

Clinical colorectal cancer, 2017-03, Vol.16 (1), p.16-22

2017

Volltextzugriff (PDF)

Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients

Lung cancer (Amsterdam, Netherlands), 2015-06, Vol.88 (3), p.319-324

2015

Volltextzugriff (PDF)

BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: A population-based study

Breast (Edinburgh), 2007-06, Vol.16 (3), p.280-292

2007

Volltextzugriff (PDF)

1 – 25 von 35

Suche als RSS-Feed

Aktive Filter

KollektionElsevier ScienceDirect Journals Complete

ThemaFemale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(35)

Publikationsform

Artikel
(35)

Sprache

Englisch
(35)

Erscheinungsjahr

n.n

Thema

Humans
(35)
Life Sciences & Biomedicine
(34)
Science & Technology
(34)
Oncology
(32)
Aged
(29)
Male
(29)
Middle Aged
(28)
Hematology, Oncology And Palliative Medicine
(20)
Lung Neoplasms - Drug Therapy
(20)
Adult
(18)
Respiratory System
(18)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(16)
Aged, 80 And Over
(15)
Treatment Outcome
(15)
Biological And Medical Sciences
(14)
Lung Neoplasms - Pathology
(14)
Pulmonary/respiratory
(14)
Lung Neoplasms - Mortality
(13)
Medical Sciences
(13)

14 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(35)
Access via ScienceDirect (Elsevier)
(35)
Ingenta
(30)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(26)
Journals@Ovid
(5)
IngentaConnect Journals
(4)
EZB Electronic Journals Library
(1)

2 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial

The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC

Palliative Short-Course Radiation Therapy in Rectal Cancer: A Phase 2 Study

Gene mutations in small-cell lung cancer (SCLC): Results of a panel of 6 genes in a cohort of Italian patients

Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer

Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: A pooled analysis of topotecan second-line trials

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non–small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors

Patterns of renal toxicity from the combination of pemetrexed and pembrolizumab for advanced nonsquamous non-small-cell lung cancer (NSCLC): A single-center experience

The pathogenic and colonization potential of Candida africana

Prognostic role of hyponatremia in 564 small cell lung cancer patients treated with topotecan

Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME)

BOLERO-3 results: pharmacological activity or pharmacokinetic effect?

Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC)

Evaluation of the VeriStrat® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study

Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) study

Overcoming Primary Resistance to PD-1 Inhibitor With Anti–PD-L1 Agent in Squamous-Cell NSCLC: Case Report

Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed–carboplatin

Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): Study of a comprehensive panel of molecular markers

Different clinical effects upon separate inhibition of coexisting EGFR and PI3KCA mutations in a lung adenocarcinoma patient

Preoperative Chemoradiation with VMAT-SIB in Rectal Cancer: A Phase II Study

Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients

Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLC

BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: A population-based study

Italian Multicenter Phase III Randomized Study of Cisplatin–Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive Stage Small Cell Lung Cancer: Treatment Rationale and Protocol Design of the GOIRC-AIFA FARM6PMFJM Trial

Aktive Filter

Suchergebnisse filtern